Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity
The present invention pertains to a compound of formula (I) wherein R 1 , R 2 , R 3 , and R 4 are each hydrogen or sulfate monoester with the proviso that R 1 , R 2 , R 3 , and R 4 cannot simultaneously be hydrogen, processess for their preparation and their use as pharmaceuticals in the treatment of CNS disorders.
1 ) Compounds of general formula (I)
wherein
R 1 , R 2 , R 3 , and R 4 denote hydrogen or sulfate monoester with the proviso that R 1 , R 2 , R 3 , and R 4 cannot simultaneously represent hydrogen, or a pharmacalogically acceptable salt thereof.
2 ) Compounds of general formula (I) according to claim 1 wherein two or three of the four radicals R 1 , R 2 , R 3 , and R 4 denote hydrogen.
3 ) Compound according to claim 1 or 2 , selected form the group consisting of
or pharmacalogically acceptable salt thereof.
4 ) Process for the preparation of compounds of general formula (I) according to one or more of claims 1 to 3 , characterized in that a compound of general formula (II)
wherein R 1 , R 2 , R 3 and R 4 denote hydroxy or hydrogen and at least one among R 1 , R 2 , R 3 and R 4 is hydroxy, is reacted with a sulfation reagent.
5 ) Process for the preparation of compounds of general formula (I) according to one or more of claims 1 to 3 , characterized in that a compound of general formula (III),
wherein R 1 , R 2 , R 3 and R 4 denote protected sulfate monoester or hydrogen and at least one among R 1 , R 2 , R 3 and R 4 is a protected sulfate monoester, is reacted with a cleavage reagent to restore the free acid moiety.
6 ) Compound of formula (I) according to one or more of claims 1 to 3 for use as a medicament.
7 ) Pharmaceutical compositions comprising as an active ingredient a compound of formula (I) according to one or more of claims 1 to 3 in admixture with one or more pharmaceutical carriers, diluents or excipients.
8 ) Use of a compound of formula (I) according to one or more of claims 1 to 3 , optionally in form of the pharmacologically acceptable salts thereof for preparing a medicament for preventing and/or treating diseases in which the use of therapeutic effective amounts of compounds displaying affinity for the 5-HT 1A and 5-HT 2 -receptor may have a therapeutic benefit.
9 ) Use of a compound of formula (I) according to one or more of claims 1 to 3 , optionally in form of the pharmacologically acceptable salts thereof for preparing a medicament for preventing and/or treating sexual disorders.
10 ) Use according to claim 9 wherein the sexual disorder is selected from the group consisting of Sexual Desire Disorders, Sexual Arousal Disorders, Orgasmic Disorders, Sexual Pain Disorders, Sexual Dysfunction due to a General Medical Condition, Substance-Induced Sexual Dysfunction, and Sexual Dysfunction not otherwise specified.
11 ) Use according to claim 10 wherein the Sexual Desire Disorder is Hypoactive Sexual Desire Disorder.
12 ) Use of a compound of formula (I) according to one or more of claims 1 to 3 , optionally in form of the pharmacologically acceptable salts thereof for preparing a medicament for preventing and/or treating premenstrual disorders.